Physician profile
Jonathan David Mccrary
NPI 1962972968
$13,318.60
in general payments reported to CMS, 2019-2025
42 companies · $2,169 in 2025
The $2,169 reported for 2025 was more than what 95% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,478 · 2022: $2,984 · 2023: $2,898 · 2024: $2,790 · 2025: $2,169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,799 · Education: $57.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,798.86 |
| Education | $57.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,558.38 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,909.07 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,369.96 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $966.92 | 2021-2025 | Stelara, Tremfya |
| Gilead Sciences, INC. | $644.29 | 2021-2025 | |
| Ardelyx, INC. | $621.51 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $537.01 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $449.39 | 2022-2025 | Dupixent |
| Qol Medical, LLC | $419.68 | 2021-2025 | Sucraid, Sucraid |
| Celgene Corporation | $384.64 | 2021-2024 | Zeposia |
| Pfizer INC. | $320.38 | 2021-2025 | |
| Ironwood Pharmaceuticals, INC | $295.97 | 2021-2024 | Linzess |
| Evoke Pharma, INC. | $290.42 | 2021-2025 | Gimoti |
| Aimmune Therapeutics, INC. | $287.15 | 2024-2025 | Zenpep, Vowst |
| Madrigal Pharmaceuticals | $256.03 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $224.22 | 2021-2024 | Keytruda, Dificid |
| Braintree Laboratories, INC. | $188.77 | 2021-2023 | Sutab |
| Phathom Pharmaceuticals, INC. | $147.72 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $145.20 | 2021-2023 | |
| Ipsen Biopharmaceuticals, INC | $141.26 | 2025 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $137.51 | 2021-2025 | Ocaliva |
| Lexicon Pharmaceuticals, INC. | $137.41 | 2024 | |
| Lilly USA, LLC | $130.39 | 2024-2025 | Omvoh |
| Celltrion USA INC. | $126.58 | 2024-2025 | Zymfentra, Vegzelma |
| E.R. Squibb & Sons, L.L.C. | $123.90 | 2022 | |
| Redhill Biopharma INC. | $71.81 | 2021 | |
| Shield Therapeutics INC | $58.46 | 2023-2025 | Accrufer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.30 | 2023 | Cyltezo |
| Fresenius Kabi USA, LLC | $47.91 | 2023-2024 | Idacio |
| Exact Sciences Corporation | $33.31 | 2023 | Cologuard Collection Kit |
| Amgen INC. | $32.77 | 2022-2025 | Uplizna |
| Neurocrine Biosciences, INC. | $25.88 | 2022 | |
| Organon LLC | $24.32 | 2023 | Renflexis |
| Janssen Scientific Affairs, LLC | $23.46 | 2024 | Stelara |
| Medtronic, INC. | $22.41 | 2023 | Interstim |
| Novo Nordisk INC | $19.52 | 2025 | Wegovy |
| Daiichi Sankyo INC. | $19.36 | 2022 | |
| Biocon Biologics INC | $16.64 | 2025 | Yesintek |
| Axonics, INC. | $16.55 | 2024 | Axonics |
| Intra-Sana Laboratories | $15.65 | 2022 | |
| Alfasigma USA, INC. | $14.12 | 2022 | |
| Tersera Therapeutics LLC | $12.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Mccrary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.